Ocular Therapeutix (OCUL) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Ocular Therapeutix (OCUL) overview

Ocular Therapeutix (OCUL) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 52.0m and operating profit of USD -270m; the year-end share price was 12.14 USD and market capitalisation was USD 2,621m. Ocular Therapeutix is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Ocular Therapeutix's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 654mFY 2025
Share price12.14 USDFY 2025 year end
RevenueUSD 52.0mFY 2025
Operating profitUSD -270mFY 2025
Net earningsUSD -266mFY 2025
Market capitalisationUSD 2,621mFY 2025 year end

About Ocular Therapeutix

Ocular Therapeutix develops and commercializes ophthalmic products using its ELUTYX bioresorbable hydrogel technology. Its approved product DEXTENZA treats inflammation and pain after eye surgery and itching associated with allergic conjunctivitis. The company is also developing AXPAXLI for wet age-related macular degeneration and diabetic retinal disease, and OTX-TIC for glaucoma and ocular hypertension.

Generate the Ocular Therapeutix report

Ocular Therapeutix is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Ocular Therapeutix and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Ocular Therapeutix

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.